<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81750">
  <stage>Registered</stage>
  <submitdate>28/07/2004</submitdate>
  <approvaldate>28/07/2004</approvaldate>
  <actrnumber>ACTRN12607000100493</actrnumber>
  <trial_identification>
    <studytitle>A paired double blind randomised comparison of Cavilon TM Durable Barrier Cream TM (CDBC) to 10% Glycerine ('Sorbolene') Cream in the prophylactic management of post-mastectomy irradiation skin care</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 04.01 - A paired double blind randomised comparison of Cavilon TM Durable Barrier Cream TM (CDBC) to 10% Glycerine ('Sorbolene') Cream in the prophylactic management of post-mastectomy irradiation skin care to reduce overall skin reactions.</scientifictitle>
    <utrn />
    <trialacronym>TROG 04.01</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR587</secondaryid>
    <secondaryid>ClinicalTrials.gov: NCT00193908</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-mastectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Test Group 1: Apply Cavilon TM Durable Barrier Cream TM (CDBC - 1.3% dimethicone) to medial of the breast and sorbolene (10% Glycerine) to lateral side. Applied from day 1 post X-Ray Therapy (XRT) until 2 weeks XRT (approximately 7 weeks).  All products applied topically.   
Test Group 2: Apply Cavilon TM Durable Barrier Cream TM (CDBC- 1.3% dimethicone) to lateral side of the breast and sorbolene (10% Glycerine) to the medial side. Applied from day 1 post X-Ray Therapy (XRT) until 2 weeks XRT (approximately 7 weeks).  All products applied topically.
NB.  The dose of the creams is daily application of a thin film to the treated area.</interventions>
    <comparator>Cavilon TM Durable Barrier Cream TM (CDBC - 1.3% dimethicone)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Skin Acute Toxicity using NCI Common Terminology Criteria for Adverse Events v3.0 acute skin scoring. 
Also measured by: 
1. Clinician (radiation oncologist or nurse) score of skin reactions.
2. Digital photo for blinded evaluation.
3. Patient comfort scores.</outcome>
      <timepoint>Weekly skin scoring during XRT treatment and weekly skin assessments continue until week 12 or until resolution of skin reaction.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age 18 or more years.  No upper limit.2. Post total mastectomy.  Timing is not of relevance to this study therefore no limit.3. Planned dose at least 45 Gy in 25 fractions.4. Eastern Co-operative Oncology Group (ECOG) 0-2.5. Able to attend weekly during treatment for review and photo and up to 6 weeks after radiotherpay if reaction does not resolve prior.6. Patients capable of childbearing using adequate contraception.7. written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion:1. previous radiotherapy to the chest wall to be treated, either as definitive treatment or as entry/exit dose from previuos intra-thoracic malignancy radiotherapy.2. Macroscopic cutaneous involvement by malignancy at time of radiotherapy.3. patients who are pregnant or lactating4. known allergy to product contents</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone/computer</concealment>
    <sequence>Stratified allocation: treatment centre. Simple randomisation by computer.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>subjects, treating physicians/nurses, statistician</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>3/03/2004</anticipatedstartdate>
    <actualstartdate>3/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/07/2007</actualenddate>
    <samplesize>300</samplesize>
    <actualsamplesize>333</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Barwon Health - Geelong Hospital campus - Geelong</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Westmead Private Hospital - Westmead</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Mater Private Hospital - South Brisbane</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Peter Graham</primarysponsorname>
    <primarysponsoraddress>Cancer Care Centre St George Hospital Kogarah NSW 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>3M supply the cavilon and sorbolene creams</fundingname>
      <fundingaddress>3M Australia
950 Pacific Hwy
Pymble, NSW, 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St George Clinical Trials Unit</fundingname>
      <fundingaddress>Cancer Care Centre St George Hospital Kogarah NSW 2217</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study has patients using two different moisturising creams during radiation therapy after mastectomy. These are Cavilon and sorbolene. It is hypothesised that skin reactions may be reduced by the Cavilon cream compared to sorbolene.</summary>
    <trialwebsite />
    <publication>
 Graham P, Plant N, Graham J, Browne L, Martin Borg M, Capp A, Delaney, Harvey J, Kenny L, Francis M, Zissiadis Y.  Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. JMIRO. 2012 Aug; 56 (4): 458-463. 

 Graham PH, Plant N, Browne L,  Borg M,  Capp A,  Delaney G, Harvey J,  Kenny L, Francis M,  Zissiadis Y.  A paired double blind randomised comparison of a moisturising durable barrier cream (MDBC) to 10% glycerine ("Sorbolene") cream in the prophylactic management of post-mastectomy irradiation skin care. Trans Tasman Radiation Oncology Group (TROG) 04.01. Internat J Radiat Oncol Biol Phys. 2013 May 1; 85(1): 45-50.  Doi: 10.1016/j.ijrobp.2012.12.009.    </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate>10/10/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress>Liverpool, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Centre, QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress>Randwick, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress>Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Perth, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress>Kogarah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworhville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wollongong Hospital</ethicname>
      <ethicaddress>Wollongong, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Graham</name>
      <address>Cancer Care Centre
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 9350 3934</phone>
      <fax>+61 2 9350 3958</fax>
      <email>Peter.Graham@SESIAHS.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Natalie Plant</name>
      <address>Cancer Care Centre
St George Hospital
Kogarah NSW 2217</address>
      <phone>+61 2 9350 2844</phone>
      <fax>+61 2 9350 2960</fax>
      <email>Natalie.Plant@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Erin Nolan</name>
      <address>Department of Radiation Oncology Locked Bag 7 Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 4014 3912</phone>
      <fax>+61 2 4014 3902</fax>
      <email>Erin.Nolan@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Natalie Plant</name>
      <address>Cancer Care Centre St George Hospital Kogarah NSW 2217</address>
      <phone>+61 2 9350 2844</phone>
      <fax />
      <email>Natalie.Plant@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>